BRCA1 and prostate carcinoma: For example, ERBB2 alterations co-segregate strongly with BRCA1 and are known to be associated with tumor aggressiveness in primary prostate cancer, tumor progression and invasion in advanced prostate cancer, and shorter time to castration-resistance (8).